APA

Friedberg J. W., Mahadevan D., Cebula E., Persky D., Lossos I., Agarwal A. B., Jung J., Burack R., Zhou X., Leonard E. J., Fingert H., Danaee H. & Bernstein S. H. (20140228). Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chicago

Friedberg Jonathan W, Mahadevan Daruka, Cebula Erin, Persky Daniel, Lossos Izidore, Agarwal Amit B, Jung Jungah, Burack Richard, Zhou Xiaofei, Leonard E Jane, Fingert Howard, Danaee Hadi and Bernstein Steven H. 20140228. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Harvard

Friedberg J. W., Mahadevan D., Cebula E., Persky D., Lossos I., Agarwal A. B., Jung J., Burack R., Zhou X., Leonard E. J., Fingert H., Danaee H. and Bernstein S. H. (20140228). Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLA

Friedberg Jonathan W, Mahadevan Daruka, Cebula Erin, Persky Daniel, Lossos Izidore, Agarwal Amit B, Jung Jungah, Burack Richard, Zhou Xiaofei, Leonard E Jane, Fingert Howard, Danaee Hadi and Bernstein Steven H. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20140228.